All News

RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

d Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Fails to Prevent COVID-19

d Jack Cush, MD

There is a preponderance and mounting evidence that hydroxychloroquine is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons.

Read Article
FDA-Building_1.png

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

d Jack Cush, MD

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Read Article
covid.corona

Adverse Events with Anti-malarials during the COVID Pandemic

d Jack Cush, MD

For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.

Read Article
injection.sites_.isr_.needle.jpg

Health Canada Approves Subcutaneous Infliximab Biosimilar

d Jack Cush, MD

The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab.

Read Article
infusion.biologic.jpg

Low Persistence of Biologics in Psoriatic Arthritis

d Jack Cush, MD

A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients

Read Article
More on Vagal Nerve Stimulation in RA (https://t.co/OykGWP76qd) The device used was an earbud, designed to deli)ver electrical pulse sequences to target the cholinergic anti-inflammatory pathway. They called this neural input methodology, e-mmunotherapy https://t.co/iubW0sZgIs https://t.co/cKlzRXKkLT

Links:

Dr. John Cush RheumNow ( View Tweet)
Adverse Events with Anti-malarials during the COVID Pandemic Despite very preliminary mixed results, the endorsement of chloroquine and hydroxychloroquine use to treat COVID-19 led substantial use (and drug shortages) for these drugs. https://t.co/UQYo3a8ZKI

Links:

Dr. John Cush RheumNow ( View Tweet)

Health Canada Approves Subcutaneous Infliximab Biosimilar The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. https://t.co/7pS7y4sys9

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 3 cross-sectional & 2case-control studies shows that the risk of developing #RA is elevated in patients with Crohns colitis (RR = 3.14; 95% CI: 2.46–4.01) and ulcerative colitis (RR = 2.29; 95% CI: 1.76–2.97) https://t.co/TIpd6lh5IZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--13 New Agents in Rheumatoid Arthritis https://t.co/s2U8qm1lLs

Links:

Dr. John Cush RheumNow ( View Tweet)

FORBES - Novel ideas on telemedicine from the former CEO of Kaiser Permanente Dr. Robert Pearl https://t.co/g6VtQ2K1j1

Links:

Dr. John Cush RheumNow ( View Tweet)

Congratulations to Dr. Daniel Kastner for winning the 2021 Crafoord Prize in Polyarthritis, “for establishing the concept of autoinflammatory diseases.” The Royal Swedish Academy of Sciences and the Crafoord Foundation issue this award annually. https://t.co/yj218sGcwG

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - When RA Meets UC Ulcerative Colitis is complicating RA therapy https://t.co/a0LPvqPe1t

Links:

Dr. John Cush RheumNow ( View Tweet)

Don’t Hold the Benlysta, Take the Vaccine The RheumNow podcast is available on Soundcloud, https://t.co/fxtCOkxTER, and Apple/Android car play. https://t.co/34XMLMZGMH

Links:

Dr. John Cush RheumNow ( View Tweet)

Download Available-- Osteoarthritis vs. Rheumatoid Arthritis https://t.co/qvVEcKqNAM

Links:

Dr. John Cush RheumNow ( View Tweet)

Consults in Cars--have telehealth consults gone too far? https://t.co/INbKZ3xxty https://t.co/X2RwktCd2U

Links:

Dr. John Cush RheumNow ( View Tweet)
Vagal Nerve Stimulation in Rheumatoid Arthritis Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate rheumatoid arthritis (RA) disease activity. https://t.co/AuoeDLM5rF https://t.co/8Mv7EYlVWZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Persistence of Biologics in Psoriatic Arthritis A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients. https://t.co/CzQnpAnttW https://t.co/uYU778rwod

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - "I Don't Know"--What to Say When you Don't Have a Diagnosis to Deliver https://t.co/HcJAXRYTyc

Links:

Dr. John Cush RheumNow ( View Tweet)

×